REDWOOD CITY, CA / ACCESSWIRE / June 5, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...
Chronic Total Occlusion Market to Surge with Demand for Advanced, High-Precision Interventional Devices Valued at US$2.44 billion in 2024. The market is projected to reach US$4.22 billion by 2031, ...
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based ...
(updated March 25, 2017) Dr Seung-Jung Park from the Asan Medical Center in Seoul South Korea presented the DECISION-CTO trial at the American College of Cardiology (ACC) 2017 Scientific Sessions. [1] ...
There is no difference in 10-year mortality between patients whose total occlusion lesions had been successfully reopened by PCI or CABG, as compared with those in whom revascularization or ...
Performing PCI on a chronic total occlusion (CTO), or in fact doing any type of transcatheter intervention, is associated with a significant stress response for the interventional cardiologist beyond ...
REDWOOD CITY, CA / ACCESSWIRE / January 9, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results